Trial reportDrug and alcohol dependence2018
Incremental validity of estimated cannabis grams as a predictor of problems and cannabinoid biomarkers: Evidence from a clinical trial.
Trial report in Drug and alcohol dependence, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 43 citations in OpenAlex.
- N-acetylcysteine for youth cannabis use disorder: randomized controlled trial main findings.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Trial
- Who responds to a multi-component treatment for cannabis use disorder? Using multivariable and machine learning models to classify treatment responders and non-responders.Addiction (Abingdon, England) · 2023Trial
- Characterizing cannabis use reduction and change in functioning during treatment: Initial steps on the path to new clinical endpoints.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2022Trial
- Evaluating cannabis use risk reduction as an alternative clinical outcome for cannabis use disorder.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2022Trial
- Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder.Psychopharmacology · 2020Trial
- Distinct circulating monocyte profiles in chronic cannabis users compared to cocaine users without changes in plasma levels of proinflammatory cytokines and LPS.NeuroImmune pharmacology and therapeutics · 2025Article
- Commentary on Borodovsky et al.: Enhancing research on THC quantification-Consumer awareness through accurate labelling.Addiction (Abingdon, England) · 2025Article
- Quantity of delta-9-tetrahydrocannabinol consumption and cannabis use disorder among daily cannabis consumers.Addiction (Abingdon, England) · 2025Article
- Persistent increased severity of cannabis use disorder symptoms in adolescents compared to adults: a one-year longitudinal study.European archives of psychiatry and clinical neuroscience · 2025Observational
- Association of Cannabis Use Reduction With Improved Functional Outcomes: An Exploratory Aggregated Analysis From Seven Cannabis Use Disorder Treatment Trials to Extract Data-Driven Cannabis Reduction Metrics.The American journal of psychiatry · 2024Article
- A test of competing mediators linking trouble sleeping to cannabis use in adolescents and emerging adults.Experimental and clinical psychopharmacology · 2024Article
- Typical Hits, Grams, or Joints: Evaluating Cannabis Survey Measurement Strategies for Quantifying Consumption.Cannabis and cannabinoid research · 2024Article
- Assessing Cannabis Use in People with Psychosis.Cannabis and cannabinoid research · 2024Review
- Cannabis use and its association with psychopathological symptoms in a Swiss adult population: a cross-sectional analysis.Frontiers in public health · 2024Article
- Exploring survey methods for measuring consumption quantities of cannabis flower and concentrate products.The American journal of drug and alcohol abuse · 2023Article
- Measuring cannabis quantities in online surveys: A rapid review and proposals for ways forward.International journal of methods in psychiatric research · 2023Review
- Evaluating cannabis exposure in survey items: Insights, strategies, and remaining challenges identified from cognitive interviewing.Drug and alcohol dependence reports · 2023Article
- Differentiating people who use cannabis heavily through latent class analysis.Substance abuse treatment, prevention, and policy · 2023Article
- CannaCount: an improved metric for quantifying estimates of maximum possible cannabinoid exposure.Scientific reports · 2023Observational
- Determining the impact of cannabis use and severity on tobacco cessation outcomes: study protocol for a prospective tobacco treatment trial.BMC psychology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundQuantifying cannabis use is complex due to a lack of a standardized packaging system that contains specified amounts of constituents. A laboratory procedure has been developed for estimating physical quantity of cannabis use by utilizing a surrogate substance to represent cannabis, and weighing the amount of the surrogate to determine typical use in grams.
methodThis secondary analysis utilized data from a multi-site, randomized, controlled pharmacological trial for adult cannabis use disorder (N=300), sponsored by the National Drug Abuse Treatment Clinical Trials Network, to test the incremental validity of this procedure. In conjunction with the Timeline Followback, this physical scale-based procedure was used to determine whether average grams per cannabis administration predicted urine cannabinoid levels (11-nor-9-carboxy-Δ9-tetrahydrocannabinol) and problems due to use, after accounting for self-reported number of days used (in the past 30 days) and number of administrations per day in a 12-week clinical trial for cannabis use disorder.
resultsLikelihood ratio tests suggest that model fit was significantly improved when grams per administration and relevant interactions were included in the model predicting urine cannabinoid level (X
conclusionsThis study provides support for the use of a scale-based method for quantifying cannabis use in grams. This methodology may be useful when precise quantification is necessary (e.g., measuring reduction in use in a clinical trial).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.